Free Trial

Microbix Biosystems Q4 2023 Earnings Report

Microbix Biosystems logo
C$0.40 +0.03 (+8.11%)
(As of 12/20/2024 05:17 PM ET)

Microbix Biosystems EPS Results

Actual EPS
-C$0.01
Consensus EPS
-C$0.01
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Microbix Biosystems Revenue Results

Actual Revenue
$4.26 million
Expected Revenue
$4.80 million
Beat/Miss
Missed by -$540.00 thousand
YoY Revenue Growth
N/A

Microbix Biosystems Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Microbix Biosystems Earnings Headlines

Microbix Biosystems Reports Record Revenue Growth
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
Microbix Reports Record Product Sales for Q4 and Fiscal 2024
Microbix Schedules Release of Results for Q4 Fiscal 2024
Microbix Assisting EMQN with Novel Genetic-Test EQA Program
See More Microbix Biosystems Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Microbix Biosystems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Microbix Biosystems and other key companies, straight to your email.

About Microbix Biosystems

Microbix Biosystems (TSE:MBX), a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

View Microbix Biosystems Profile

More Earnings Resources from MarketBeat

Upcoming Earnings